# LVGN6051

Source: https://onco.cc/drugs/lvgn6051/  
OnCo record `lvgn6051` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

LVGN6051 is a monoclonal antibody from Lyvgen Biopharma Holdings Limited, in registered phase 2 trials for head and neck squamous cell carcinoma.

## Summary

LVGN6051 is listed on ClinicalTrials.gov as an intervention in 1 registered phase 2 trial sponsored by Lyvgen Biopharma Holdings Limited, in head and neck squamous cell carcinoma. A monoclonal antibody, as described in the registry record. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest; registry-only
- Code: LVGN6051
- Modality: Monoclonal antibody
- Mechanism: A monoclonal antibody, as described in the registry record.

## Sources

- ClinicalTrials.gov: trials of LVGN6051: https://clinicaltrials.gov/search?intr=LVGN6051

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/)
- trials: [A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)](https://onco.cc/trials/nct06378177/)

---
JSON: https://onco.cc/api/v1/entities/lvgn6051.json